Nutex Health (NASDAQ:NUTX) Rating Lowered to “Buy” at Wall Street Zen

Nutex Health (NASDAQ:NUTX) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other research analysts have also recently commented on NUTX. Lake Street Capital started coverage on Nutex Health in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $235.00 price target on the stock. Weiss Ratings cut shares of Nutex Health from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, July 10th. Zacks Research upgraded shares of Nutex Health to a “hold” rating in a research note on Monday, June 29th. Finally, B. Riley Financial started coverage on shares of Nutex Health in a report on Friday, June 26th. They issued a “buy” rating and a $290.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Nutex Health currently has a consensus rating of “Moderate Buy” and an average target price of $243.33.

Nutex Health Trading Up 4.2%

Shares of NASDAQ:NUTX opened at $168.27 on Monday. The company has a market capitalization of $1.16 billion, a P/E ratio of 13.00 and a beta of 0.21. Nutex Health has a 1 year low of $77.21 and a 1 year high of $204.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.14 and a quick ratio of 3.12. The business’s 50 day simple moving average is $150.12 and its 200 day simple moving average is $130.56.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings data on Thursday, April 30th. The company reported $6.52 EPS for the quarter, topping analysts’ consensus estimates of $3.99 by $2.53. The firm had revenue of $216.49 million for the quarter, compared to analyst estimates of $227.80 million. Nutex Health had a return on equity of 23.50% and a net margin of 10.95%. On average, research analysts anticipate that Nutex Health will post 22.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Nutex Health

Institutional investors have recently modified their holdings of the business. Islay Capital Management LLC bought a new stake in shares of Nutex Health during the 4th quarter worth $34,000. BNP Paribas Financial Markets raised its stake in Nutex Health by 966.7% during the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after acquiring an additional 290 shares in the last quarter. Royal Bank of Canada raised its stake in Nutex Health by 752.4% during the fourth quarter. Royal Bank of Canada now owns 358 shares of the company’s stock worth $59,000 after acquiring an additional 316 shares in the last quarter. Osaic Holdings Inc. raised its stake in Nutex Health by 280.3% during the fourth quarter. Osaic Holdings Inc. now owns 810 shares of the company’s stock worth $133,000 after acquiring an additional 597 shares in the last quarter. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Nutex Health in the first quarter worth about $83,000. Institutional investors and hedge funds own 5.32% of the company’s stock.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.